Portage Biotech Inc <PRTG.O>: Losses of 6  cents announced for second quarter

29 November 2022 10:05 p.m. ​All figures in US dollars. The loss announced by Portage Biotech Inc in the second quarter were higher than the Refinitiv mean estimate of losses. The company reported losses of -6 cents per share, 16 cents higher than the same quarter last year when the company reported EPS of -22 cents. Losses of -29 cents per share were anticipated by the three analysts providing estimates for the quarter. Wall Street expected results to range from -33 cents to -26 cents per share, with a forecasted mean of -29 cents per share. The company reported zero revenue, which is in line with the estimated revenue. RECOMMENDATIONS * The consensus recommendation for the company is "Buy". * The average consensus recommendation for the biotechnology & medical research peer group is also "Buy". FORECAST CHANGES * Three analysts are currently providing Refinitiv with estimates. * In the last week there have been no earnings estimate revisions by analysts covering the company. There was no change to the number of estimates. YEAR OVER YEAR * The company reported revenue of $0, a revenue figure is not available for the same quarter last year,​ * Previous quarterly performance (using earnings preferred measure) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET, MISSED Jun. 30 2022 -0.30​ -0.13 Beat Mar. 31 2022 -0.28 -0.56 Missed Dec. 31 2021 -0.27 -0.26 Beat​ Sep. 30 2021 -0.25 -0.22 Beat This summary was machine generated from Refinitiv data November 29 at 10:05 p.m.